Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Phase 3

A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s

https://clinicaltrials.gov/ct2/show/NCT03329508?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: P2B001;   Drug: Rasagiline;   Drug: Pramipexole;   Drug: Pramipexole ER
Sponsor:   Pharma Two B Ltd.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03329508

FIRST POSTED:
Mon, 06 Nov 2017 12:00:00 EST

LAST UPDATE POSTED:
08/29/19 10:25AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03329508?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F15%2F2019&lupd_d=14&sort=nwst

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Melatonin on Clock Genes in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Melatonin;   Drug: Placebos
Sponsor:   Instituto Mexicano del Seguro Social
Enrolling by invitation

CLINICALTRIALS.GOV IDENTIFIER:
NCT04287543

FIRST POSTED:
Thu, 27 Feb 2020 12:00:00 EST

LAST UPDATE POSTED:
02/27/20 09:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04287543?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=02%2F13%2F2020&lupd_d=14&sort=nwst

Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03391882?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations

Study
STUDY TITLE:
A Study of an Investigational Drug to See How it Affects the People With Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes) Compared to an Approved Drug Used to Treat People With Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)

DESCRIPTION:
Condition:   Motor OFF Episodes Associated With Parkinson’s Disease
Interventions:   Drug: APL-130277;   Drug: subcutaneous apomorphine
Sponsor:   Sunovion
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03391882

FIRST POSTED:
Fri, 05 Jan 2018 12:00:00 EST

LAST UPDATE POSTED:
05/15/19 07:32AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03391882?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure

https://clinicaltrials.gov/ct2/show/NCT04095793?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F05%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure

DESCRIPTION:
Condition:   Symptomatic Neurogenic Orthostatic Hypotension
Intervention:   Drug: ampreloxetine
Sponsor:   Theravance Biopharma
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04095793

FIRST POSTED:
Thu, 19 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/19/19 08:06AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04095793?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F05%2F2019&lupd_d=14&sort=nwst

A Clinical Trial Investigating the Efficacy, Safety and Tolerability of ND0612 Infusion in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT04006210?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations (BouNDless).

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Combination Product: ND0612 Solution for SC infusion;   Combination Product: Placebo for SC infusion;   Drug: Carbidopa and Levodopa 25mg/100mg;   Drug: Placebo for Carbidopa and Levodopa 25mg/100mg
Sponsor:   NeuroDerm Ltd.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04006210

FIRST POSTED:
Wed, 03 Jul 2019 12:00:00 EDT

LAST UPDATE POSTED:
07/05/19 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04006210?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Hydrogen;   Drug: Placebo oral tablet
Sponsor:   Stony Brook University
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03971617

FIRST POSTED:
Mon, 03 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/03/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03971617?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F20%2F2019&lupd_d=14&sort=nwst

Effects of Lingzhi (Ganoderma) on Disease Progression in Patients With Untreated Early Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03594656?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Ganoderma;   Drug: Placebos
Sponsor:   Xuanwu Hospital, Beijing
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03594656

FIRST POSTED:
Fri, 20 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/29/19 07:29AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03594656?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F15%2F2019&lupd_d=14&sort=nwst

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations

https://clinicaltrials.gov/ct2/show/NCT03670953?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F02%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations

DESCRIPTION:
Condition:   Parkinson’s Disease (Disorder)
Interventions:   Drug: IR CD-LD;   Drug: IPX203 ER CD-LD;   Other: IPX203 placebo;   Other: IR CD-LD placebo
Sponsor:   IMPAX Laboratories, Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03670953

FIRST POSTED:
Fri, 14 Sep 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/16/19 07:19AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03670953?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F02%2F2019&lupd_d=14&sort=nwst